Introduction
The main objective of organic and medicinal chemistry is the design, synthesis, and production of molecules having precious value as human therapeutic agents for the treatment of various human diseases, e.g., cancer, human immunodeficiency virus (HIV), and hepatitis C virus (HCV), which are the major scourges of humanity.
A literature survey revealed that pyrazolo [1,5-a] pyrimidines are of considerable chemical and pharmacological importance as purine analogues. The class of pyrazolopyrimidines possesses a broad spectrum of biological effectiveness such as antimicrobial, 1 anti-inflammatory, 2 cytotoxicity, 3 and hepatitis C virus inhibitor 4 activities.
On the other hand, Schiff bases are an important class of compounds in the medicinal field, with biological applications including antimicrobial, 5 antioxidant, 6 anti-inflammatory, 7 antitumor, 8 and α -glucosidase enzyme inhibitor. 9 Furthermore, we have found that a Schiff base is a prominent group in the structures of some drugs, e.g., dantrolene (muscle relaxant), nifuroxazide (antibiotic), and thiacetazone (antituberculosis) (as shown in Figure 1 ).
In view of the above-mentioned biological importance of pyrazolo [1,5-a ] pyrimidines and Schiff bases and as a continuation of our interest in the synthesis of novel compounds with expected biological activities, 10, 11 we found that compounds 7-amino-6-cyano-2-(4-methoxyphenylamino)-5-(naphthalen-1-yl)pyrazolo [1,5- respectively. 12 Furthermore, 2-(4-methoxyphenylamino)-5,7-dimethyl-N -phenylpyrazolo [1,5-a ] pyrimidine-3-carboxamide (III) is an example of a pyrazolo [1,5-a] pyrimidine derivative that exhibited promising anticancer activity in Ehrlich ascites carcinoma assay (as shown in Figure 2 ). 13 We report herein the synthesis of a new series of pyrazolo [1,5-a] pyrimidine derivatives and Schiff bases based on 5-aminopyrazole derivatives, and also investigation of the cytotoxic activities of the synthesized compounds against four human tumor cell lines (HCT116 "colon", A549 "lung", HepG2 "liver", and MCF-7 "breast" cancers).
Thiacetazone (Anti-tuberculosis) 
Results and discussion

Chemistry
The starting compounds, 5-amino-3-(4-methoxyphenylamino)-N -aryl-1H -pyrazole-4-carboxamides 1a-c, 13 were utilized for preparing the target compounds (Schemes 1-3). The reaction of compounds 1a-c with ethyl acetoacetate 2 in glacial acetic acid under reflux temperature afforded the 7-hydroxy-5-methyl-N -(aryl)pyrazolo [1,5- a]pyrimidines 5a-c. The formation of compounds 5a-c was therefore assumed to proceed via the initial attack of the exocyclic amino group of 1a-c on the keto group of ethyl acetoacetate 2, followed by intramolecular cyclization via elimination of ethanol (Scheme 1). The structures of 5a-c were confirmed on the basis of their analytical and spectral data. Compound 5c, taken as a representative example, revealed the molecular formula corresponding to the carbonyl carbon, and a signal at 171.9 due to C 7 (C 7 -OH) of the pyrazolopyrimidine nucleus. Fluorinated compounds have been of interest to medicinal chemists for many years because of their biological activities such as antiviral, 14 antitumor, 15 antitubercular, 16 anti-inflammatory, and antimicrobial. 17−19 In addition, we have found that some fluorinated compounds such as 5-fluorouracil, paroxetine, and ciprofloxacin are available as drugs (as shown in Figure 3 ). For these reasons, we were encouraged to synthesize a num- The formation of compounds 9a-c was assumed to proceed via initial attack of the exocyclic amino function of the compounds 1a-c on the α , β -unsaturated system in compound 6, followed by intramolecular The importance of Schiff bases in the pharmaceutical field prompted us to synthesize some new Schiff bases 11a-f by the condensation of 5-amino-N -aryl-1 H -pyrazole-4-carboxamides 1a-c with 5-methylfuran-2-carbaldehyde 10a or ferrocene-2-carboxaldehyde 10b in boiling ethanol using a catalytic amount of triethylamine (Scheme 3). The structures of 11a-f were characterized and confirmed on the basis of analytical and spectral data (IR, MS, 1 H NMR, and 13 C NMR 
In vitro cytotoxic activity
The cytotoxic activity of the tested compounds was determined using the SRB assay 21 against four human cancer cell lines: colon HCT116, lung A549, liver HepG2, and breast MCF-7 (Table) . The results are expressed as the IC 50 (µ g/mL), which is the concentration of a drug that causes a 50% reduction in the proliferation of cancer cells when compared to the growth of the control cells. Doxorubicin was used as a reference drug. The tumor cells showed normal growth in the culture system and DMSO did not seem to have any noticeable effect on cellular growth. The results revealed that all the tested compounds {pyrazolo [1,5-a] pyrimidines 5a-c and 9a-c, and Schiff bases 11b-f } did not exert any activity against human colon HCT116 cancer cell lines.
In the case of human lung A549 cancer cell lines, the tested compounds {pyrazolo [1,5- a ]pyrimidines 9a-c and Schiff bases 11b-f } had no effect on the cancer cell lines, but compound 5a (IC 50 = 5.00 ± 0.50 µ g/mL) was found to be more potent than the standard drug, doxorubicin (IC 50 = 5.10 ± 0.50 µ g/mL). Compounds 5b (IC 50 = 5.60 ± 0.60 µ g/mL) and 5c (IC 50 = 5.45 ± 0.62 µ g/mL) showed cytotoxicity close to that of the standard drug (IC 50 = 5.10 ± 0.50 µ g/mL).
For liver HepG2 cancer cell lines, while compounds 9a, 9b, 11b, and 11e had no effect on the cancer cell lines, compound 5a (IC 50 = 4.00 ± 0.44 µ g/mL) was found to be more potent than the standard drug (IC 50 = 4.20 ± 0.46 µ g/mL). On the other hand, compound 8c (IC 50 = 4.50 ± 0.55 µ g/mL) was nearly as potent as the reference drug (IC 50 = 4.20 ± 0.46 µ g/mL), but compounds 5b (IC 50 = 6.50 ± 0.75 µ g/mL), 5c (IC 50 = 6.10 ± 0.62 µ g/mL), and 11d (IC 50 = 6.20 ± 0.70 µ g/mL) revealed slight activity in comparison with the standard drug (IC 50 = 4.20 ± 0.46 µ g/mL), while the rest of the tested compounds, 11c (IC 50 = 19.20 ± 2.00 µ g/mL) and 11f (IC 50 = 15.90 ± 1.70 µ g/mL), were less potent than the standard drug (IC 50 = 4.20 ± 0.46 µ g/mL).
From the estimation of the cytotoxic activity on the human breast MCF-7 cancer cell lines, compounds 9a, 9b, and 11e had no effect on the cancer cells, but compounds 5a (IC 50 = 4.60 ± 0.55 µ g/mL) and 5c (IC 50 = 4.20 ± 0.60 µ g/mL) showed cytotoxicity more potent than the standard drug (IC 50 = 4.70 ± 0.55 µ g/mL). Compound 9c (IC 50 = 4.90 ± 0.50 µ g/mL) showed cytotoxic activity close to that of the standard drug (IC 50 = 4.70 ± 0.55 µg/mL), but compounds 5b (IC 50 = 5.90 ± 0.62 µ g/mL) and 11d (IC 50 = 7.00 ± 0.80 µ g/mL) revealed slight activity in comparison with the standard drug (IC 50 = 4.70 ± 0.55 µ g/mL), while the rest of the tested compounds, 11b (IC 50 = 32.00 ± 3.30 µ g/mL), 11c (IC 50 = 17.10 ± 1.80 µ g/mL) and 11f (IC 50 = 24.70 ± 2.50 µ g/mL), were less potent than the standard drug (IC 50 = 4.70 ± 0.55 µ g/mL).
Based on these results, it is evident that there is a structure-activity relationship (SAR). From the screening of the tested compounds against the lung A549, liver HepG2, and breast MCF-7 cell lines, some derivatives bearing the phenyl group were more active than those bearing the 4-chlorophenyl group and those bearing the 4-methylphenyl group. Thus, on lung A549 cell lines, 5a (IC 50 = 5.00 ± 0.50 µ g/mL) > 5c (IC 50 = 5.45 ± 0.62 µ g/mL) > 5b (IC 50 = 5.60 ± 0.60 µ g/mL). Moreover, the screening of the tested compounds against the HepG2 (liver) cell lines showed that 5a (IC 50 = 4.00 ± 0.44 µ g/mL) > 5c (IC 50 = 6.10 ± 0.62 µ g/mL) > 5b (IC 50 = 6.50 ± 0.75 µ g/mL) and 11d (IC 50 = 6.20 ± 0.70 µ g/mL) > 11f (IC 50 = 15.90 ± 1.70 µ g/mL) > 11e (N.A.). Furthermore, on breast MCF-7 cell lines, 11d (IC 50 = 7.00 ± 0.80 µ g/mL) > 11f (IC 50 = 24.70 ± 2.50 µ g/mL) > 11e (N.A.).
Finally, compound 5a showed cytotoxic activity and was more potent against the lung A549 and liver HepG2 cell lines, with IC 50 = 5.00 ± 0.50 µ g/mL and IC 50 = 4.00 ± 0.44 µ g/mL, respectively, and compound 5c showed cytotoxic activity and was more potent against the breast MCF-7 cell lines, with IC 50 = 4.20 ± 0.60 µ g/mL.
Conclusion
In the present work, we report the synthesis, characterization, and in vitro cytotoxic activity of novel pyrazolo [1,5- a]pyrimidines 5a-c and 9a-c and Schiff bases 11a-f. The cytotoxicity results of the above-mentioned compounds against four human cancer cell lines (colon HCT116, lung A549, liver HepG2, and breast MCF-7) indicated that two compounds, 5a and 5c, showed cytotoxicity and growth inhibitor activity on lung A549, liver HepG2, and breast MCF-7 cancer cell lines at low concentrations in comparison with the reference drug considered (doxorubicin).
Experimental
All melting points were measured on a Gallenkamp melting point apparatus and are uncorrected. The IR spectra were recorded (KBr disk) on a PerkinElmer 1650 FT-IR instrument.
1 H NMR (300 or 500 MHz) and Progress of the reactions was monitored by thin-layer chromatography (TLC) using aluminum sheets coated with silica gel F 254 (Merck); viewing under a short-wavelength UV lamp effected detection. All evaporations were carried out under reduced pressure at 40
• C.
Chemistry 4.1.1. Synthesis of 5-amino-3-(4-methoxyphenylamino)-N -aryl-1H -pyrazole-4-carboxamides (1a-c)
Compounds of this series (1a-c) were prepared according to the literature procedure. 
Synthesis of 7-hydroxy-2-(4-methoxyphenylamino)-5-methyl-N -(aryl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (5a-c)
A mixture of compounds 1a-c (0.01 mol) with ethyl acetoacetate 2 (0.01 mol) in glacial acetic acid (20 mL) was refluxed for 6 h, then poured onto crushed ice, and the separated solid was filtered off, dried well, and recrystallized from ethanol to afford compounds 5a-c.
7-Hydroxy-2-(4-methoxyphenylamino)-5-methyl-N -phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide (5a)
Pale yellow crystals, mp > 300 
7-Hydroxy-2-(4-methoxyphenylamino)-5-methyl-N -(4-methylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (5b)
Pale yellow crystals, mp 260-261 • C, yield (79%). IR (KBr) ν max /cm −1 3339, 3055 (OH, NH), 1667 (C=O). 
7-Amino-6-cyano-5-(4-fluorophenyl)-2-(4-methoxyphenylamino)-N -(4-methylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (9b)
Yellow crystals, mp > 300 
3-(4-Methoxyphenylamino)-5-(ferrocen-2-ylmethyleneamino)-N -(4-chlorophenyl)-1H -pyrazole-4-carboxamide (11f )
Reddish-brown crystals, mp 110-112 o C, yield (69% 
Evaluation of cytotoxic activity in vitro
The cytotoxic activity was measured in vitro using the Sulforhodamine-B stain (SRB) assay according to the previously reported standard procedure. 21 Cells were inoculated in a 96-well microtiter plate (10 4 cells/well) for 24 h before treatment with the tested compounds to allow attachment of cells to the wall of the plate. The tested compounds were dissolved in DMSO and diluted with saline to the appropriate volume. Different concentrations of the tested compounds under testing (0-100 µ g/mL) were added to the cells. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compounds for 48 h at 37 • C and in an atmosphere of 5% CO 2 . After 48 h, cells were fixed, washed, and stained for 30 min with 0.4% (w/v) SRB dissolved in 1% acetic acid. The unbound dye was removed by four washes with 1% acetic acid and attached stain was recovered with tris-EDTA buffer. Color intensity was measured in an ELISA reader at wavelength 540 nm. The relation between the surviving fraction and drug concentration was plotted to obtain the survival curve for each cell line after the specified time. The concentration required for 50% inhibition of cell viability (IC 50 ) was calculated and the results are given in the Table.
Statistical analysis
The results are reported as mean ± standard error (S.E.) {where mean ± SE = mean ± SD √ n ; n = 6 experiments}.
